The JAVELIN study was a single-arm prospective clinical trial evaluating the efficacy and toxicity profile of avelumab, an anti-PDL-1 monoclonal antibody, in 53 patients with predominantly pleural and peritoneal mesothelioma [40]. The gene discussed is CD274; the disease is peritoneal mesothelioma.